SOSV

Hoofprint Biome is a biotechnology company that develops probiotics and natural enzymes to enhance the sustainability of ruminant livestock production. Their products improve cattle health and digestive care by reducing methane emissions, thereby enabling the livestock industry to adopt more sustainable practices through microbiome engineering.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Hoofprint Biome is a biotechnology company that develops probiotics and natural enzymes to enhance the sustainability of ruminant livestock production. Their products improve cattle health and digestive care by reducing methane emissions, thereby enabling the livestock industry to adopt more sustainable practices through microbiome engineering.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

AlkaLi Labs is a biotechnology research company founded in 2023 and based in San Francisco, California. The company focuses on developing biological solutions to unlock domestic mineral resources. Currently operating in stealth mode, AlkaLi Labs aims to innovate in the field of biotechnology by leveraging natural processes to enhance resource extraction and sustainability.

BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

OneSkin Inc. is a biotechnology company based in San Francisco, California, that focuses on developing innovative solutions to combat skin aging. Founded by a team of four PhDs and longevity scientists, the company specializes in creating advanced human 3D skin models for research, development, and validation of skincare products, including new anti-aging compounds. OneSkin has developed a proprietary peptide, OS-01, which is designed to reduce the biological age of the skin by decreasing the accumulation of aged cells, enhancing cellular repair capacity, and strengthening the epidermal barrier. The company's flagship product, OS-01 Topical Supplement, is formulated to target the root causes of skin aging and is suitable for all skin types. In addition to its product offerings, OneSkin provides in vitro testing services using its animal-free 3D human tissue models, facilitating efficacy and safety assessments for the cosmetic and ingredient supplier industries.

Laguna Bio is a biotechnology company focused on cancer treatment through its innovative drug discovery platform. Founded in 2022 and headquartered in Berkeley, California, the company specializes in selectively activating and expanding the innate immune system to combat solid tumors. By enhancing the response rate of bispecific antibody drugs, Laguna Bio aims to provide specific T cells that strengthen the immune system's ability to fight cancer, ultimately improving survival rates for patients facing this deadly disease.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

DNAzyme is a biotechnology company specializing in the development of enzymes derived from Antarctic extremophile microorganisms as active ingredients for skin health applications. Utilizing recombinant DNA repair technology, the company produces highly pure enzymes at an industrial scale, enabling clinicians to create innovative solutions for skin health and rejuvenation in both the cosmetic and pharmaceutical industries.

heXem bio specializes in recording solutions for the early development of humans for longevity.

ZiO Health is a biotechnology company focused on enhancing patient outcomes through its innovative pocket-sized laboratory testing technology. The company has developed proprietary biosensor devices that utilize machine learning algorithms to provide real-time results tailored to individual patient profiles. These multi-functional electronic devices are designed for measuring, testing, and detecting the molecular composition of various chemical and biological substances, enabling users to assess the presence, absence, or quantity of specific target molecules. By delivering quality home diagnostics and personalized testing solutions, ZiO Health aims to empower individuals to optimize their health and prevent illness.

CellCo provides next generation biologics and biotherapies by integrating synthetic biology and AI.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

CellCrine focuses on discovering enzymes that transform cell culture for the cell-based meats industry. CellCrine was founded in 2021and was headquartered in United, States.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the development of treatments for complex diseases such as cancer and age-related disorders.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

Lillianah Technologies is a company dedicated to developing innovative carbon capture technology aimed at restoring marine ecosystems affected by pollution and other environmental challenges. Comprising a team of scientists, Lillianah focuses on optimizing the biological pump in oceans, which is crucial for maintaining ecological balance. By harnessing the ocean's potential, the company seeks to address the detrimental impacts of human activity, such as fertilizer runoff, and contribute to reversing environmental degradation. Through its efforts, Lillianah Technologies aspires to create sustainable solutions that benefit both the oceans and the broader environment.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

Xias Bio is a biotechnology startup focused on the development and production of recombinant proteins. The company specializes in creating non-immunogenic natural motifs that enhance the delivery of functionalities for various applications in research, beauty, and healthcare. Xias Bio's innovative platform provides a versatile, animal product-free biomaterial that offers tailored biological functionality. This approach enables pharmaceutical and cosmetic companies to access designer proteins that serve as non-immunogenic, non-toxic alternatives to traditional synthetic and animal-derived materials. By improving attributes such as gel and film formation, as well as antioxidant properties, Xias Bio addresses the limitations of conventional solutions, positioning itself as a valuable partner in the biotechnology sector.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Allozymes is a prominent deep technology company that specializes in the application of ultrahigh-throughput microfluidics technology to enhance the evolution and development of enzymes. The company focuses on creating sensitive and accurate assays for enzymatic reactions, utilizing proprietary microfluidic chips and proteomics technologies. Allozymes' platform integrates molecular biology and process engineering to produce high-purity enzymes tailored for specific applications. This innovative approach enables clients to expedite custom enzyme development and to create novel, sustainable natural products, positioning Allozymes as a leader in the enzyme development sector.

Hexafly is a biotech company based in Kells, Ireland, established in 2016. It specializes in the sustainable farming of insects, particularly the Black Soldier Fly larvae, to produce various products for the aquaculture, animal feed, and plant nutrition sectors. The company focuses on converting food waste into protein meals, oils, and fertilizers, promoting a circular economy. Its product range includes insect oil for fish feed, protein additives for aquaculture, Frass for plant nutrition, and Chitin, a versatile bio-polymer utilized in medicine, cosmetics, and food. Hexafly sells its products online, aiming to provide environmentally friendly solutions in agriculture and contribute to a sustainable food system.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

TippingPoint Biosciences is focused on developing innovative therapeutics that address diseases caused by defects in DNA packaging, with an emphasis on conditions such as cancer and neurodegenerative disorders. Utilizing a specialized drug discovery platform, the company aims to identify new treatment options that specifically target unique genome packaging states associated with various diseases. This approach not only facilitates the treatment of cancer but also holds potential for advancing stem cell therapies by correcting dysfunctional genome packaging. Through its research and development efforts, TippingPoint Biosciences seeks to provide effective solutions for complex medical challenges.

AlkaLi Labs is a biotechnology research company founded in 2023 and based in San Francisco, California. The company focuses on developing biological solutions to unlock domestic mineral resources. Currently operating in stealth mode, AlkaLi Labs aims to innovate in the field of biotechnology by leveraging natural processes to enhance resource extraction and sustainability.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

Gozen Bioworks offers solutions and biomaterials developed with a biomimicry approach by combining science, art, philosophy, and design to raise awareness and provide help to the planet, living creatures, and humanity. They develop and invent high-performance microbe-derived materials from natural inputs, such as next-generation leather, biotextiles, bioplastics, packaging, and interior materials.

Kresko RNAtech is a biotechnology company focused on the development and production of nutraceuticals. It specializes in identifying bioactive ribonucleic acids (RNAs) from natural sources, utilizing advanced techniques such as machine learning and bioinformatics. By discovering RNAs that may offer health benefits, Kresko RNAtech aims to assist researchers in enhancing human well-being and addressing the challenges posed by stressful and changing environments through innovative RNA technologies.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Kolibri is a biotechnology company focused on revolutionizing large-scale cell culture to enhance accessibility and affordability in cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that employs advanced techniques in acoustics and biology, enabling its bioreactors to achieve a 90-fold increase in cell yield while significantly reducing production costs by up to 50 times. Kolibri's innovative bioreactors are designed to facilitate the efficient growth of cells at scale, thereby supporting partners in drug development and providing critical solutions for unlocking patient access to gene therapies and next-generation vaccines. Through its technological advancements, Kolibri aims to address key challenges in the bioproduction of biologics.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

PILI Inc. is a biotechnology company based in Paris, France, that specializes in the research and manufacturing of bio-fabricated colors using microorganisms. Founded in 2012, the company focuses on developing enzymes and fermentation biotechnologies that transform sugar into renewable and durable dyes and pigments. By offering a sustainable alternative to traditional toxic and non-recyclable inks, PILI aims to replace petrochemical and vegetable-based colorants with organic dyes produced at an industrial scale. The company's innovative approach not only promotes sustainable development but also enables businesses to reduce costs while utilizing environmentally friendly materials.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

Dia has invented an electrochemical sensor that can measure a wide variety of chemical biomarkers non-invasively in saliva or sweat. The data is sent via Bluetooth to an app on the user’s smartphone and analyzed in real-time. From the app, it can be securely sent to a third party. To date, we have measured hormones, electrolytes, neurotransmitters and metabolites. At DIA, we let the biology dictate which analyte we put on which platform – our wearable arm sleeve for sweat or our table-top device for saliva – because some biomarkers, such as cortisol fluctuate throughout the day and need to be monitored through a wearable sensor, while others, such as creatinine are more suitable to a daily saliva test.

Lillianah Technologies is a company dedicated to developing innovative carbon capture technology aimed at restoring marine ecosystems affected by pollution and other environmental challenges. Comprising a team of scientists, Lillianah focuses on optimizing the biological pump in oceans, which is crucial for maintaining ecological balance. By harnessing the ocean's potential, the company seeks to address the detrimental impacts of human activity, such as fertilizer runoff, and contribute to reversing environmental degradation. Through its efforts, Lillianah Technologies aspires to create sustainable solutions that benefit both the oceans and the broader environment.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

BioCraft Pet Nutrition is a biotechnology company focused on creating sustainable and nutritious pet food for dogs and cats. Established in 2016 and based in Philadelphia, Pennsylvania, the company specializes in developing all-natural, organic products that incorporate innovative ingredients such as probiotics, nutritional yeast, and cultured meat. BioCraft aims to promote the health of pets while minimizing environmental impact and animal harm. The company's unique approach leverages green biotechnology to produce its offerings, which are available for purchase online. Through its commitment to sustainability and animal welfare, BioCraft Pet Nutrition stands out as a pioneer in the pet food industry.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

OneSkin Inc. is a biotechnology company based in San Francisco, California, that focuses on developing innovative solutions to combat skin aging. Founded by a team of four PhDs and longevity scientists, the company specializes in creating advanced human 3D skin models for research, development, and validation of skincare products, including new anti-aging compounds. OneSkin has developed a proprietary peptide, OS-01, which is designed to reduce the biological age of the skin by decreasing the accumulation of aged cells, enhancing cellular repair capacity, and strengthening the epidermal barrier. The company's flagship product, OS-01 Topical Supplement, is formulated to target the root causes of skin aging and is suitable for all skin types. In addition to its product offerings, OneSkin provides in vitro testing services using its animal-free 3D human tissue models, facilitating efficacy and safety assessments for the cosmetic and ingredient supplier industries.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

Michroma Corporation is a biotechnology company that specializes in producing natural thermostable colorants derived from filamentous fungi for the food and cosmetics industries. Founded in 2019, the company operates from locations in San Francisco, California, and Rosario, Argentina. By leveraging synthetic biology, Michroma develops proprietary fungal strains that can be cultivated in bioreactors, allowing for the sustainable and cost-effective production of high-performance ingredients. Its initial offerings focus on pH-stable and heat-stable colorants, which are designed to replace synthetic pigments and those sourced from animals and plants. In addition to colorants, Michroma is also engaged in the production of mycoprotein and other innovative ingredients, collaborating with leading companies in the food and beverage and cosmetic sectors.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Gozen Bioworks offers solutions and biomaterials developed with a biomimicry approach by combining science, art, philosophy, and design to raise awareness and provide help to the planet, living creatures, and humanity. They develop and invent high-performance microbe-derived materials from natural inputs, such as next-generation leather, biotextiles, bioplastics, packaging, and interior materials.

Laguna Bio is a biotechnology company focused on cancer treatment through its innovative drug discovery platform. Founded in 2022 and headquartered in Berkeley, California, the company specializes in selectively activating and expanding the innate immune system to combat solid tumors. By enhancing the response rate of bispecific antibody drugs, Laguna Bio aims to provide specific T cells that strengthen the immune system's ability to fight cancer, ultimately improving survival rates for patients facing this deadly disease.

Hexafly is a biotech company based in Kells, Ireland, established in 2016. It specializes in the sustainable farming of insects, particularly the Black Soldier Fly larvae, to produce various products for the aquaculture, animal feed, and plant nutrition sectors. The company focuses on converting food waste into protein meals, oils, and fertilizers, promoting a circular economy. Its product range includes insect oil for fish feed, protein additives for aquaculture, Frass for plant nutrition, and Chitin, a versatile bio-polymer utilized in medicine, cosmetics, and food. Hexafly sells its products online, aiming to provide environmentally friendly solutions in agriculture and contribute to a sustainable food system.

CellCrine focuses on discovering enzymes that transform cell culture for the cell-based meats industry. CellCrine was founded in 2021and was headquartered in United, States.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Chronos DX is a biotechnology research company based in London, Germany, specializing in drug development and in vitro diagnostics within the healthcare sector. The company is known for its innovative bioassay technology, which is designed for diagnostics, drug screening, and development. Chronos DX focuses on creating high-performance, low-cost, and scalable technology capable of detecting a variety of biomarkers, including cell-free DNA, micro proteins, exosomes, and metabolites. This technology provides medical professionals with a platform for in-line and in vivo monitoring of biomarkers, enhancing the capabilities of diagnostics and drug development in medical practice.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, founded in 2016. It operates a proprietary drug discovery platform that utilizes synthetic biology to expand the druggable proteome, focusing on therapeutic applications in oncology and rare diseases. The platform employs empirical intracellular selection to identify and design compounds that can modulate protein interactions, either disrupting specific protein-protein interactions or facilitating the targeted degradation of proteins through the recruitment of E3 ubiquitin ligases. SyntheX's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that evade chemotherapy through homologous recombination. The company identifies drug targets by analyzing clinical, evolutionary, phenotypic, and structural data, and it maintains both internal oncology projects and collaborative discovery initiatives.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

Keel Labs is a biomaterials company that focuses on developing ocean-based materials derived from renewable resources, particularly seaweed. The company aims to address the ecological damage caused by the fashion industry by creating durable and rapidly degradable yarns from kelp. Through its innovative platform, Keel Labs integrates scientific design and waste management into textile production, offering an alternative to conventional textiles for the footwear and apparel industries. This approach not only provides a functional resource but also emphasizes environmental sustainability, allowing for a more responsible and accessible option in material sourcing.

BioLumen is a nutritional technology company that develops a patented dietary fiber technology platform that reduces the negative effect of a diet heavy in processed foods. BioLumen's technology is composed of insoluble dietary fiber matrix covered with a blend of food ingredients created from the latest drug delivery system research. The company's product, a nutraceutical, focuses on high risk individuals with prediabetes to help manage blood sugar levels, protect their liver from excess sugar and feed their gut microbiome, delivering health benefits. BioLumen was founded on 2018 and is headquartered in San Francisco, California.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Pregenerate, Inc., founded in 2019 and incorporated in Delaware, specializes in developing innovative organ-on-a-chip technology aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. The company's scalable models utilize human cells, allowing pharmaceutical companies to significantly reduce costs and improve drug success rates. Pregenerate's technology not only enhances the efficiency of research but also facilitates the stratification of patients into targeted treatment subgroups, enabling personalized medicine approaches. By providing these advanced solutions, Pregenerate aims to transform the research landscape and improve treatment outcomes for individuals with arthritis.

Aksense is a biotechnology company focused on developing affordable and portable nucleic acid-based diagnostic panels for the rapid and accurate detection of pathogens. It has created the first portable rapid infection diagnostic biosensor designed to enhance the quality of care in healthcare settings. Aksense aims to improve antibiotic prescribing practices and public health outcomes by enabling early detection and treatment of infections. Its technology facilitates faster recovery for patients through cost-effective molecular testing, ultimately reducing the spread of infections and improving overall patient outcomes.

AnimalBiome specializes in personalized nutrition services that focus on enhancing the gut health of dogs and cats through microbiome science. The company offers microbiome tests that assess the unique gut microbiota of individual pets, providing insights that inform tailored nutrition recommendations. Additionally, AnimalBiome develops restorative supplements made from material sourced from healthy animals, allowing for the introduction of beneficial microbes to help restore balance in the gut microbiome. By leveraging advanced diagnostic tools, including DNA sequencing, AnimalBiome enables pet owners to better understand their pets' gut health, ultimately contributing to improved well-being and a healthier lifestyle for their animals.

Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. The company focuses on improving maternal health outcomes by developing safe, affordable, and accessible home-based early detection tests for complications during pregnancy. One of its key products is a low-cost, reliable preeclampsia detection strip, which enables expectant mothers to self-screen for this serious condition. By facilitating early detection, Kalia Health aims to empower women to seek timely medical intervention, ultimately reducing the risks associated with preeclampsia and enhancing maternal health.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. The company focuses on improving maternal health outcomes by developing safe, affordable, and accessible home-based early detection tests for complications during pregnancy. One of its key products is a low-cost, reliable preeclampsia detection strip, which enables expectant mothers to self-screen for this serious condition. By facilitating early detection, Kalia Health aims to empower women to seek timely medical intervention, ultimately reducing the risks associated with preeclampsia and enhancing maternal health.

Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical solutions to address crop diseases, pests, and weeds that are otherwise difficult to manage. Utilizing patented protein evolution technology, the company has established a peptide and RNA interference delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform facilitates protein engineering through continuous laboratory evolution and advanced techniques such as phage display. This technology empowers researchers with enhanced control, reporting, recording, simulation, and remote access capabilities, thereby advancing the field of agricultural biotechnology and promoting sustainable farming practices.

Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical solutions to address crop diseases, pests, and weeds that are otherwise difficult to manage. Utilizing patented protein evolution technology, the company has established a peptide and RNA interference delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform facilitates protein engineering through continuous laboratory evolution and advanced techniques such as phage display. This technology empowers researchers with enhanced control, reporting, recording, simulation, and remote access capabilities, thereby advancing the field of agricultural biotechnology and promoting sustainable farming practices.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Hexafly is a biotech company based in Kells, Ireland, established in 2016. It specializes in the sustainable farming of insects, particularly the Black Soldier Fly larvae, to produce various products for the aquaculture, animal feed, and plant nutrition sectors. The company focuses on converting food waste into protein meals, oils, and fertilizers, promoting a circular economy. Its product range includes insect oil for fish feed, protein additives for aquaculture, Frass for plant nutrition, and Chitin, a versatile bio-polymer utilized in medicine, cosmetics, and food. Hexafly sells its products online, aiming to provide environmentally friendly solutions in agriculture and contribute to a sustainable food system.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally invented at Cornell University, Inso Biosciences enhances the efficiency of processing cellular material. The company's platform is designed to facilitate genomic analysis, including applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. By enabling healthcare and biotechnology companies to effectively separate and isolate cellular components, Inso Biosciences aims to transform the landscape of biological sample preparation.

Cellens is a medical device company based in Medford, Massachusetts, and is a spinoff from Tufts University, established in 2019. The company focuses on enhancing cancer detection through noninvasive screening methods. It has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning to assist oncologists in the detection of bladder cancer. By analyzing physio-biomarkers on cell surfaces derived from urine samples, Cellens provides a diagnostic score that helps healthcare professionals minimize the need for invasive and costly procedures, thereby improving patient outcomes in bladder cancer diagnostics.

Cellens is a medical device company based in Medford, Massachusetts, and is a spinoff from Tufts University, established in 2019. The company focuses on enhancing cancer detection through noninvasive screening methods. It has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning to assist oncologists in the detection of bladder cancer. By analyzing physio-biomarkers on cell surfaces derived from urine samples, Cellens provides a diagnostic score that helps healthcare professionals minimize the need for invasive and costly procedures, thereby improving patient outcomes in bladder cancer diagnostics.

VemiCo is a biotechnology company focused on extending healthy living by addressing the aging process. The company leverages artificial intelligence and synthetic biology to discover and advance promising molecules derived from gut microbial DNA. By harnessing the potential of microbiomes, VemiCo aims to enhance gut health and overall well-being, offering innovative solutions for medical professionals in the health sector.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Grand Bio is working to improve the efficiency with which cells create their own growth factors. The firm provides supplements that boost growth factors in the medium in which cells live and thrive.

Grand Bio is working to improve the efficiency with which cells create their own growth factors. The firm provides supplements that boost growth factors in the medium in which cells live and thrive.

Synthace Limited is a London-based company specializing in the development and operation of software solutions for various industries, including health, pharmaceuticals, food, energy, agri-science, industrial biotechnology, and manufacturing. The company offers Antha, a cloud-based platform designed to automate and enhance biological processes. This platform allows life science researchers to digitize experiments from start to finish, enabling them to design, simulate, and execute reproducible experiments with minimal training. Antha facilitates the integration of experimental data and metadata in a streamlined manner, making it easier for scientists to manage their workflows and increasing the scientific value of their research. Synthace's technology empowers researchers to conduct complex experiments without the need for coding, thereby expanding the possibilities of laboratory experimentation. Founded in 2011, Synthace also has a presence in Cambridge, Massachusetts, and maintains a strategic partnership with Microsoft.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can either inhibit or promote ferroptosis, a form of regulated cell death. By targeting this mechanism, Prothegen seeks to provide effective therapeutics that can prevent unwanted cell death, thereby improving treatment options for various diseases.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can either inhibit or promote ferroptosis, a form of regulated cell death. By targeting this mechanism, Prothegen seeks to provide effective therapeutics that can prevent unwanted cell death, thereby improving treatment options for various diseases.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Indee Labs is focused on developing innovative hardware for gene delivery, specifically designed to facilitate the efficient development and scalable manufacture of gene-modified cell therapies, such as chimeric antigen receptor T cells. The company has created a non-viral intracellular delivery system that integrates with standard reagents, optimizing the recovery of viable modified cells with minimal disruption. Utilizing microfluidic vortex shedding technology, Indee Labs' system enables the gentle delivery of macromolecules, nucleic acids, and gene-editing complexes to various cell types. The company collaborates with the Australian National Fabrication Facility for its technology development and has established lab space at Bonneville Labs in Berkeley while expanding its operations with a new office in Sydney. Indee Labs has been associated with various prestigious incubators and programs, including NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.